FDA approves Actavis’ sNDA for SAPHRIS to treat manic or mixed episodes of bipolar I disorder
The company claims that SAPHRIS is the only atypical antipsychotic treatment option with a sublingual (under the tongue) formulation. The NDA is based on the results of a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.